Viswatej Avutu

844 total citations
21 papers, 331 citations indexed

About

Viswatej Avutu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Viswatej Avutu has authored 21 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Viswatej Avutu's work include Sarcoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (6 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). Viswatej Avutu is often cited by papers focused on Sarcoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (6 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). Viswatej Avutu collaborates with scholars based in United States and France. Viswatej Avutu's co-authors include Jason E. Chan, Beatriz Wills, Melissa Lumish, Andriy Derkach, John Philip, Molly Maloy, Justin Jee, Yelena Y. Janjigian, Varun Narendra and Melissa S. Pessin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Viswatej Avutu

19 papers receiving 329 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Viswatej Avutu United States	7	250	94	74	69	40	21	331
Berta Obispo Spain	8	203 0.8×	83 0.9×	58 0.8×	28 0.4×	41 1.0×	28	295
Sue Anne McLachlan Australia	10	264 1.1×	61 0.6×	78 1.1×	79 1.1×	130 3.3×	26	576
Stephanie Smits United Kingdom	10	224 0.9×	114 1.2×	93 1.3×	14 0.2×	65 1.6×	20	474
Gry Assam Taarnhøj Denmark	13	153 0.6×	31 0.3×	33 0.4×	42 0.6×	38 0.9×	23	297
Ghada Elgohary Egypt	10	139 0.6×	71 0.8×	29 0.4×	28 0.4×	50 1.3×	31	298
Abdullah A. Alsharm Saudi Arabia	6	209 0.8×	31 0.3×	46 0.6×	24 0.3×	30 0.8×	18	307
Annette W.G. van der Velden Netherlands	10	134 0.5×	31 0.3×	41 0.6×	30 0.4×	33 0.8×	16	260
Razan Mansour Jordan	11	90 0.4×	54 0.6×	29 0.4×	30 0.4×	47 1.2×	37	281
Julia Fehniger United States	11	134 0.5×	31 0.3×	15 0.2×	40 0.6×	47 1.2×	25	397
Solomon B. Makgoeng United States	11	154 0.6×	40 0.4×	33 0.4×	30 0.4×	68 1.7×	16	339

Countries citing papers authored by Viswatej Avutu

Since Specialization

Citations

This map shows the geographic impact of Viswatej Avutu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viswatej Avutu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viswatej Avutu more than expected).

Fields of papers citing papers by Viswatej Avutu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viswatej Avutu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viswatej Avutu. The network helps show where Viswatej Avutu may publish in the future.

Co-authorship network of co-authors of Viswatej Avutu

This figure shows the co-authorship network connecting the top 25 collaborators of Viswatej Avutu. A scholar is included among the top collaborators of Viswatej Avutu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viswatej Avutu. Viswatej Avutu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Firestone, Ross, Jung Hun Oh, Viswatej Avutu, et al.. (2025). High WEE1 expression is independently linked to poor survival in multiple myeloma. Blood Cancer Journal. 15(1). 22–22.

Avutu, Viswatej, Kenneth Seier, Li-Xuan Qin, et al.. (2025). Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy. Transplantation and Cellular Therapy.

Avutu, Viswatej, J. Andrew Livingston, Noah Federman, et al.. (2024). Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma.. Journal of Clinical Oncology. 42(16_suppl). 11525–11525. 2 indexed citations

Kelly, Ciara M., Viswatej Avutu, Lauren B. Banks, et al.. (2024). Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2690–TPS2690. 2 indexed citations

Weiss, Aaron R., Safia K. Ahmed, Wendy Allen‐Rhoades, et al.. (2023). Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group. Journal of Adolescent and Young Adult Oncology. 12(5). 792–793. 1 indexed citations

Rosenbaum, Evan, Kenneth Seier, Martina Bradić, et al.. (2023). Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas. Cancer Research Communications. 3(10). 2118–2125. 6 indexed citations

Rosenbaum, Evan, Li‐Xuan Qin, Mark A. Dickson, et al.. (2023). Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology. 41(16_suppl). 11518–11518. 3 indexed citations

Movva, Sujana, Viswatej Avutu, Ping Chi, et al.. (2023). A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11517–11517. 6 indexed citations

D’Angelo, Sandra P., Evan Rosenbaum, Mark A. Dickson, et al.. (2023). A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.. Journal of Clinical Oncology. 41(16_suppl). TPS11590–TPS11590. 1 indexed citations

10.

Kelly, Ciara M., Viswatej Avutu, Ping Chi, et al.. (2023). A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.. Journal of Clinical Oncology. 41(16_suppl). 11570–11570. 7 indexed citations

11.

Mittal, Nupur, Aniket Saha, Viswatej Avutu, et al.. (2022). Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials. Scientific Reports. 12(1). 3875–3875. 16 indexed citations

12.

Avutu, Viswatej, Kathleen Lynch, Marie Barnett, et al.. (2022). Psychosocial Needs and Preferences for Care among Adolescent and Young Adult Cancer Patients (Ages 15–39): A Qualitative Study. Cancers. 14(3). 710–710. 35 indexed citations

13.

Mittal, Nupur, et al.. (2022). Creation of a quality improvement collaborative to address adolescent and young adult cancer clinical trial enrollment: ATAQI (AYA trial access quality initiative). Current Problems in Cancer. 47(6). 100898–100898. 3 indexed citations

14.

Rosenbaum, Evan, Li‐Xuan Qin, Katherine A. Thornton, et al.. (2022). A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).. Journal of Clinical Oncology. 40(16_suppl). 11516–11516. 5 indexed citations

15.

Slotkin, Emily K., Audrey Mauguen, Michael V. Ortiz, et al.. (2022). A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma.. Journal of Clinical Oncology. 40(16_suppl). 11503–11503. 8 indexed citations

16.

Avutu, Viswatej, Emily K. Slotkin, Sant P. Chawla, et al.. (2022). A phase 1/2 dose-escalation and dose-expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.. Journal of Clinical Oncology. 40(16_suppl). TPS11584–TPS11584. 3 indexed citations

17.

Avutu, Viswatej, Aaron R. Weiss, Damon R. Reed, et al.. (2021). Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. Journal of Adolescent and Young Adult Oncology. 11(3). 328–332. 6 indexed citations

18.

Rosenbaum, Evan, Sujana Movva, Ciara M. Kelly, et al.. (2021). A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.. Journal of Clinical Oncology. 39(15_suppl). 11549–11549. 9 indexed citations

19.

Jee, Justin, Michael B. Foote, Melissa Lumish, et al.. (2020). Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology. 38(30). 3538–3546. 173 indexed citations

20.

Inaba, Hiroto, Aditya H. Gaur, Xueyuan Cao, et al.. (2014). Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer. 120(13). 1985–1992. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact